4y5v - Revision history

OCA at 07:59, 3 May 2023

2023-05-03T07:59:46Z

←Older revision		Revision as of 07:59, 3 May 2023
Line 3:		Line 3:
	<StructureSection load='4y5v' size='340' side='right'caption='[[4y5v]], [[Resolution\|resolution]] 2.60Å' scene=''>		<StructureSection load='4y5v' size='340' side='right'caption='[[4y5v]], [[Resolution\|resolution]] 2.60Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4y5v]] is a 9 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Y5V OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4Y5V FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4y5v]] is a 9 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Y5V OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4Y5V FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PGE:TRIETHYLENE+GLYCOL'>PGE</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PGE:TRIETHYLENE+GLYCOL'>PGE</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4y5x\|4y5x]], [[4y5y\|4y5y]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4y5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4y5v OCA], [https://pdbe.org/4y5v PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4y5v RCSB], [https://www.ebi.ac.uk/pdbsum/4y5v PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4y5v ProSAT]</span></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">EPOR ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4y5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4y5v OCA], [~~http~~://pdbe.org/4y5v PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4y5v RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4y5v PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4y5v ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Defects in EPOR are the cause of familial erythrocytosis type 1 (ECYT1) [MIM:[~~http~~://omim.org/entry/133100 133100]]. ECYT1 is an autosomal dominant disorder characterized by increased serum red blood cell mass, elevated hemoglobin and hematocrit, hypersensitivity of erythroid progenitors to erythropoietin, erythropoietin low serum levels, and no increase in platelets nor leukocytes. It has a relatively benign course and does not progress to leukemia.<ref>PMID:8506290</ref> <ref>PMID:8174675</ref> <ref>PMID:8608241</ref>	+	[https://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN] Defects in EPOR are the cause of familial erythrocytosis type 1 (ECYT1) [MIM:[https://omim.org/entry/133100 133100]. ECYT1 is an autosomal dominant disorder characterized by increased serum red blood cell mass, elevated hemoglobin and hematocrit, hypersensitivity of erythroid progenitors to erythropoietin, erythropoietin low serum levels, and no increase in platelets nor leukocytes. It has a relatively benign course and does not progress to leukemia.<ref>PMID:8506290</ref> <ref>PMID:8174675</ref> <ref>PMID:8608241</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.	+	[https://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN] Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 24:		Line 22:

	==See Also==		==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
	*[[Erythropoietin receptor\|Erythropoietin receptor]]		*[[Erythropoietin receptor\|Erythropoietin receptor]]
	== References ==		== References ==
Line 29:		Line 28:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Garcia~~, K C~~]]	+	[[Category: Garcia KC]]
-	[[Category: Guo, F]]	+	[[Category: Guo F]]
-	[[Category: Jude~~, K M~~]]	+	[[Category: Jude KM]]
-	[[Category: Moraga, I]]	+	[[Category: Moraga I]]
-	[[Category: Ozkan, E]]	+	[[Category: Ozkan E]]
-	~~[[Category: Diabody complex]]~~	+
-	~~[[Category: Protein binding-immune system complex]]~~	+
-	~~[[Category: Receptor~~]]	+

OCA at 23:53, 5 June 2019

2019-06-05T23:53:23Z

←Older revision		Revision as of 23:53, 5 June 2019
Line 1:		Line 1:

	==Diabody 305 complex with EpoR==		==Diabody 305 complex with EpoR==
-	<StructureSection load='4y5v' size='340' side='right' caption='[[4y5v]], [[Resolution\|resolution]] 2.60Å' scene=''>	+	<StructureSection load='4y5v' size='340' side='right'caption='[[4y5v]], [[Resolution\|resolution]] 2.60Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4y5v]] is a 9 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Y5V OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4Y5V FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4y5v]] is a 9 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Y5V OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4Y5V FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PGE:TRIETHYLENE+GLYCOL'>PGE</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PGE:TRIETHYLENE+GLYCOL'>PGE</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4y5x\|4y5x]], [[4y5y\|4y5y]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4y5x\|4y5x]], [[4y5y\|4y5y]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">EPOR ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4y5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4y5v OCA], [http://pdbe.org/4y5v PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4y5v RCSB], [http://www.ebi.ac.uk/pdbsum/4y5v PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4y5v ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4y5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4y5v OCA], [http://pdbe.org/4y5v PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4y5v RCSB], [http://www.ebi.ac.uk/pdbsum/4y5v PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4y5v ProSAT]</span></td></tr>
	</table>		</table>
Line 28:		Line 29:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Garcia, K C]]		[[Category: Garcia, K C]]
	[[Category: Guo, F]]		[[Category: Guo, F]]

OCA at 01:59, 10 March 2017

2017-03-10T01:59:54Z

←Older revision		Revision as of 01:59, 10 March 2017
Line 1:		Line 1:
		+
	==Diabody 305 complex with EpoR==		==Diabody 305 complex with EpoR==
	<StructureSection load='4y5v' size='340' side='right' caption='[[4y5v]], [[Resolution\|resolution]] 2.60Å' scene=''>		<StructureSection load='4y5v' size='340' side='right' caption='[[4y5v]], [[Resolution\|resolution]] 2.60Å' scene=''>
Line 5:		Line 6:
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PGE:TRIETHYLENE+GLYCOL'>PGE</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PGE:TRIETHYLENE+GLYCOL'>PGE</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4y5x\|4y5x]], [[4y5y\|4y5y]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4y5x\|4y5x]], [[4y5y\|4y5y]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4y5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4y5v OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4y5v RCSB], [http://www.ebi.ac.uk/pdbsum/4y5v PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4y5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4y5v OCA], [http://pdbe.org/4y5v PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4y5v RCSB], [http://www.ebi.ac.uk/pdbsum/4y5v PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4y5v ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 19:		Line 20:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4y5v" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Erythropoietin receptor\|Erythropoietin receptor]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 11:38, 30 April 2015

2015-04-30T11:38:00Z

←Older revision		Revision as of 11:38, 30 April 2015
Line 1:		Line 1:
-	'''~~Unreleased~~ structure'''	+	==Diabody 305 complex with EpoR==
		+	<StructureSection load='4y5v' size='340' side='right' caption='[[4y5v]], [[Resolution\|resolution]] 2.60Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[4y5v]] is a 9 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Y5V OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4Y5V FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=PGE:TRIETHYLENE+GLYCOL'>PGE</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4y5x\|4y5x]], [[4y5y\|4y5y]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4y5v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4y5v OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4y5v RCSB], [http://www.ebi.ac.uk/pdbsum/4y5v PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Defects in EPOR are the cause of familial erythrocytosis type 1 (ECYT1) [MIM:[http://omim.org/entry/133100 133100]]. ECYT1 is an autosomal dominant disorder characterized by increased serum red blood cell mass, elevated hemoglobin and hematocrit, hypersensitivity of erythroid progenitors to erythropoietin, erythropoietin low serum levels, and no increase in platelets nor leukocytes. It has a relatively benign course and does not progress to leukemia.<ref>PMID:8506290</ref> <ref>PMID:8174675</ref> <ref>PMID:8608241</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/EPOR_HUMAN EPOR_HUMAN]] Receptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase. Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Most cell-surface receptors for cytokines and growth factors signal as dimers, but it is unclear whether remodeling receptor dimer topology is a viable strategy to "tune" signaling output. We utilized diabodies (DA) as surrogate ligands in a prototypical dimeric receptor-ligand system, the cytokine Erythropoietin (EPO) and its receptor (EpoR), to dimerize EpoR ectodomains in non-native architectures. Diabody-induced signaling amplitudes varied from full to minimal agonism, and structures of these DA/EpoR complexes differed in EpoR dimer orientation and proximity. Diabodies also elicited biased or differential activation of signaling pathways and gene expression profiles compared to EPO. Non-signaling diabodies inhibited proliferation of erythroid precursors from patients with a myeloproliferative neoplasm due to a constitutively active JAK2V617F mutation. Thus, intracellular oncogenic mutations causing ligand-independent receptor activation can be counteracted by extracellular ligands that re-orient receptors into inactive dimer topologies. This approach has broad applications for tuning signaling output for many dimeric receptor systems.

-	~~The entry 4y5v is ON HOLD~~	+	Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands.,Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo I, Weissman IL, Minary P, Majeti R, Constantinescu SN, Piehler J, Garcia KC Cell. 2015 Mar 12;160(6):1196-208. doi: 10.1016/j.cell.2015.02.011. Epub 2015 Feb, 26. PMID:25728669<ref>PMID:25728669</ref>

-	~~Authors: Moraga~~, I.~~, Guo, F~~.~~, Ozkan, E., Jude, K.M., Garcia, K.C~~.	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-		+	</div>
-	~~Description:~~	+	== References ==
-	~~[[Category: Unreleased Structures]]~~	+	<references/>
-	[[Category: ~~Ozkan~~, E]]	+	__TOC__
		+	</StructureSection>
		+	[[Category: Garcia, K C]]
	[[Category: Guo, F]]		[[Category: Guo, F]]
-	[[Category: Jude, K.M]]	+	[[Category: Jude, K M]]
-	~~[[Category: Garcia, K.C~~]]	+
	[[Category: Moraga, I]]		[[Category: Moraga, I]]
		+	[[Category: Ozkan, E]]
		+	[[Category: Diabody complex]]
		+	[[Category: Protein binding-immune system complex]]
		+	[[Category: Receptor]]

OCA: Protected "4y5v" [edit=sysop:move=sysop]

2015-02-18T12:04:08Z

Protected "4y5v" [edit=sysop:move=sysop]

←Older revision

Revision as of 12:04, 18 February 2015

OCA: New page: '''Unreleased structure''' The entry 4y5v is ON HOLD Authors: Moraga, I., Guo, F., Ozkan, E., Jude, K.M., Garcia, K.C. Description: Category: Unreleased Structures [[Category: Ozk...

2015-02-18T12:04:07Z

New page: '''Unreleased structure''' The entry 4y5v is ON HOLD Authors: Moraga, I., Guo, F., Ozkan, E., Jude, K.M., Garcia, K.C. Description: Category: Unreleased Structures [[Category: Ozk...

New page

'''Unreleased structure'''

The entry 4y5v is ON HOLD

Authors: Moraga, I., Guo, F., Ozkan, E., Jude, K.M., Garcia, K.C.

Description:
[[Category: Unreleased Structures]]
[[Category: Ozkan, E]]
[[Category: Guo, F]]
[[Category: Jude, K.M]]
[[Category: Garcia, K.C]]
[[Category: Moraga, I]]